Loading clinical trials...
Loading clinical trials...
A Phase 1 Open-label Study in Healthy Subjects to Assess the Relative Oral Bioavailability and Food Effect of Single-dose JNJ-64417184 Administered as Tablets and as Suspension
Conditions
Interventions
JNJ-64417184 600 (Oral Tablet Formulation)
JNJ-64417184 (Oral Suspension Formulation)
Locations
1
United States
PRA Health Sciences Salt Lake City Clinic
Salt Lake City, Utah, United States
Start Date
May 15, 2019
Primary Completion Date
June 22, 2019
Completion Date
June 22, 2019
Last Updated
February 3, 2025
NCT07470866
NCT00104325
NCT07221448
NCT07388667
NCT06637865
NCT07118891
Lead Sponsor
Janssen Research & Development, LLC
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions